|
End-of-day quote
Taipei Exchange
16/10/2026
|
5-day change | 1st Jan Change | ||
| 166.00 TWD | +1.22% |
|
-5.14% | +318.14% |
| 08-14 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-28 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: Lin BioScience, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 6,987 | 12,832 | 12,583 | 8,946 | 10,812 | 32,842 |
| Change | - | 83.66% | -1.94% | -28.9% | 20.85% | 203.76% |
| Enterprise Value (EV) 1 | 5,900 | 12,027 | 10,985 | 5,728 | 5,637 | 16,572 |
| Change | - | 103.86% | -8.67% | -47.85% | -1.59% | 193.97% |
| P/E | -41.7x | -29.4x | -39.8x | -12.3x | -14.5x | -23.9x |
| PBR | 7.66x | 23.7x | 10.2x | 4.19x | 3.79x | 3.06x |
| PEG | - | -0x | 1.3x | -0x | -7.44x | -0.3x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -30.1x | -35.7x | -24.8x | -5.25x | -3.88x | -5.82x |
| EV / EBIT | -29.9x | -35.6x | -24.7x | -5.22x | -3.87x | -5.8x |
| EV / FCF | 41.5x | -381x | -16.7x | -9.01x | -9.83x | -36.2x |
| FCF Yield | 2.41% | -0.26% | -5.99% | -11.1% | -10.2% | -2.77% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.2444 | -0.6318 | -0.4371 | -0.9288 | -0.9469 | -1.66 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -195.8 | -336.8 | -442.6 | -1,091 | -1,451 | -2,849 |
| EBIT 1 | -197 | -338.3 | -445.1 | -1,097 | -1,458 | -2,857 |
| Net income 1 | -151.8 | -434.7 | -313.5 | -687.2 | -744.3 | -1,363 |
| Net Debt 1 | -1,087 | -804.6 | -1,599 | -3,218 | -5,174 | -16,270 |
| Reference price 2 | 10.20 | 18.60 | 17.40 | 11.40 | 13.75 | 39.70 |
| Nbr of stocks (in thousands) | 685,000 | 689,895 | 723,188 | 784,760 | 786,298 | 827,250 |
| Announcement Date | 08/04/21 | 25/04/22 | 25/04/23 | 23/04/24 | 30/04/25 | 28/04/26 |
1TWD in Million2TWD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 4.24B | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 29.05x | 6.95x | 18.39x | 2.15% | 394.51B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 6696 Stock
- Valuation Lin BioScience, Inc.
Select your edition
All financial news and data tailored to specific country editions
